Lipoprotein(a) Lowering Therapies Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is lipoprotein(a) lowering therapies market size?

USD 946.0 million in 2026 and USD 2,198.8 million by 2036 at an 8.8% CAGR.

Sales of lipoprotein(a) lowering therapies are estimated to rise at 8.8% CAGR through 2036, increasing valuation from USD 946.0 million in 2026 to USD 2,198.8 million by 2036. Medical specialists focus heavily on advanced heart disease treatments to improve patient outcomes. Specialist interest specifically centers on hepatic apolipoprotein(a) suppression through durable RNA medicines. Ongoing clinical research tracks the progress of these new therapies. United States National Library of Medicine updated pelacarsen CAVS study enrollment to 502 participants in June 2026. Revised enrollment supports continued evaluation across calcific valve disease.

Different global healthcare networks evaluate new cardiovascular therapies based on distinct regional priorities. United States and United Kingdom health systems prioritize outcome evidence and specialist lipid pathways during therapy review. Japan and South Korea care networks emphasize referral discipline and consistent cardiovascular diagnostics. New trial data continually reinforces these regional evaluations. Nissen and colleagues reported randomization of 320 participants in March 2025. Such specific trial strengthens evidence for prolonged lepodisiran activity.

Summary of Lipoprotein(a) Lowering Therapies Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Lipoprotein(a) lowering therapy selection progresses as specialists connect inherited cardiovascular risk with measurable treatment response. Program decisions reflect outcome evidence and repeatable patient identification across cardiology services. Cardiology teams seek dedicated medicines for patients retaining residual risk following optimized LDL management. Specialist laboratories support treatment selection due to consistent lipoprotein(a) measurement across referred populations. Outcome trials remain central to coverage decisions across cardiovascular prevention programs and payer reviews. Infrequent dosing profiles are anticipated to support adherence across long-duration treatment pathways. Hospital participation is expected to influence early uptake across complex secondary prevention populations.
Product and Segment View	Segment direction is led by antisense oligonucleotides, followed by atherosclerotic cardiovascular disease and hospitals. Clinical review is expected to center on target specificity and outcome evidence across specialist pathways. Antisense oligonucleotides are likely to represent 41.1% share in 2026 owing to established LPA messenger RNA suppression programs. Atherosclerotic cardiovascular disease is anticipated to account for 34.2% share in 2026, led by measurable cardiovascular event endpoints. Hospitals are estimated to secure 33.2% share in 2026, backed by specialist cardiology services and trial-ready infrastructure.
Geography and Growth Outlook	Country movement varies due to clinical trial participation and specialist lipid service availability. Local testing pathways influence patient identification across national cardiovascular systems. United States is predicted to scale at 10.6% CAGR through 2036, influenced by extensive outcome-trial participation. United Kingdom is set to rise at 10.1% CAGR during forecast period, aided by organized cardiology pathways. Japan is projected to record 9.4% CAGR from 2026 to 2036, guided by tertiary-care concentration and laboratory consistency.
Competitive View	Competition centers on modality durability and evidence supporting cardiovascular benefit across specialist populations. Commercial progress favors companies combining trial execution with dependable medical education. Novartis and Eli Lilly are expected to compete based on advanced programs covering injectable RNA medicines and oral treatment formats. Amgen is projected to support market review depending on olpasiran development across primary and secondary prevention pathways. Ionis Pharmaceuticals and Silence Therapeutics are anticipated to contribute specialized RNA medicine experience across partnered development programs.
Analyst Perspective	Lipoprotein(a) lowering therapies support preventive planning for inherited risk requiring specialist measurement and sustained follow-up. Commercial progress is expected to improve through outcome proof and repeatable referral pathways. Clinical leaders assess treatment utility led by biomarker durability and cardiovascular event evidence across complete care pathways. Hospital teams value medicines supporting specialist care without disrupting established lipid-lowering treatment plans. Regional testing access improves confidence during expansion across new cardiology services and trained clinical groups. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is lipoprotein(a) lowering therapies market segmented?

The lipoprotein(a) lowering therapies industry is segmented by therapy type, target, indication, end user, and region.

The lipoprotein(a) lowering therapies market is segmented by therapy type, target, indication, end user, and region. Therapy type coverage includes antisense oligonucleotides and small interfering RNA medicines supported by oligonucleotide API. PCSK9 inhibitors and lipoprotein apheresis represent established alternatives. Target coverage addresses LPA gene and apolipoprotein(a) supported by PCSK9 and LDL receptor pathways. Indication coverage includes atherosclerotic cardiovascular disease and familial hypercholesterolemia followed by elevated lipoprotein(a) and secondary cardiovascular prevention. End-user coverage spans hospitals and specialty cardiology clinics supported by ambulatory care centers and academic research institutes. Regional coverage includes North America and Latin America followed by Europe and East Asia. South Asia with Oceania and Middle East and Africa completes geographic assessment.

Why do antisense oligonucleotides shape therapy-type demand?

Antisense oligonucleotides suppress apolipoprotein(a) production led by sequence-specific messenger RNA binding. United States National Library of Medicine records updated in May 2026 listed 8,323 participants within the pelacarsen cardiovascular outcomes study. Such advanced program strengthens clinical familiarity with targeted Lp(a) reduction across specialist cardiovascular services.

• Antisense oligonucleotides are projected to represent 41.1% share in 2026, driven by advanced clinical development and established dosing evidence. Cardiovascular teams assess durability and safety monitoring before incorporating these therapies into specialist treatment pathways.
• Small interfering RNA therapies support prolonged target suppression through infrequent subcutaneous administration. PCSK9 inhibitors and lipoprotein apheresis serve patients requiring broader lipid control or immediate Lp(a) removal.

Why does the LPA gene lead target selection?

The LPA gene controls hepatic apolipoprotein(a) production and inherited Lp(a) concentrations. A July 2025 American Heart Association publication estimated elevated Lp(a) levels among 1 in 5 Americans. The inherited prevalence supports therapies designed to interrupt production near its principal biological source.

• In 2026, the LPA gene is anticipated to account for 32.3% share in 2026 due to its direct connection with apolipoprotein(a) production. Developers prioritize selective gene-expression control to deliver substantial Lp(a) reductions beyond conventional LDL-lowering mechanisms.
• Apolipoprotein(a) targeting supports precise protein reduction across RNA-based therapeutic programs. PCSK9 and LDL receptor pathway approaches provide complementary lipid control across patients carrying several cardiovascular risks.

Why does atherosclerotic cardiovascular disease lead indication demand?

Atherosclerotic cardiovascular disease provides measurable endpoints for assessing cardiovascular benefits from Lp(a) reduction. A January 2026 United States Centers for Disease Control and Prevention report recorded 683,491 heart disease deaths during 2024. It reinforces outcome studies involving myocardial infarction and stroke across high-risk populations.

• Based on indication, atherosclerotic cardiovascular disease is forecast to capture 34.2% share in 2026 since it is led by defined cardiovascular endpoints and identifiable high-risk patients. Trial sponsors evaluate major adverse cardiovascular events instead of relying exclusively on biomarker reductions.
• Familial hypercholesterolemia and elevated Lp(a) identify inherited-risk populations requiring earlier specialist intervention. Secondary cardiovascular prevention supports treatment across patients facing persistent risk under standard lipid management.

Why do hospitals lead end-user demand?

Hospitals combine lipid testing and cardiovascular imaging with specialist consultation and trial monitoring. Eli Lilly and Company reported in June 2026 an ACCLAIM-CTA enrollment target of 252 participants. Such trial requirements favor institutions equipped for longitudinal assessment and cardiovascular safety monitoring.

• By end-user, hospitals are estimated to secure 33.2% share in 2026 owing to cardiologist access and diagnostic infrastructure. These institutions identify eligible patients and supervise emerging therapies across complex secondary-prevention populations.
• Specialty cardiology clinics support routine Lp(a) testing and continuing treatment across stable high-risk patients. Ambulatory care centers and academic research institutes contribute injection services and clinical evidence development.

What are drivers, restraints, and opportunities in lipoprotein(a) lowering therapies market?

Inherited cardiovascular risk and emerging clinical evidence promote targeted therapy review. Outcome uncertainty and inconsistent testing may delay routine use across general cardiology pathways.

• Driver: Dedicated medicines provide deeper lipoprotein(a) suppression than conventional lipid treatments across genetically elevated patient groups. Measurable biomarker response supports specialist interest across residual-risk pathways.
• Restraint: Payers and clinicians require cardiovascular outcome proof prior to routine prescribing across broad patient populations. Variable testing thresholds are likely to delay consistent treatment eligibility decisions.
• Opportunity: Testing programs create identifiable treatment populations through cardiology referrals and in vitro diagnostics. Structured follow-up connects laboratory results with specialist treatment review.

Broader treatment flexibility influences adoption among patients preferring convenient long-term therapy formats. Nicholls and colleagues reported placebo-adjusted muvalaplin reductions reaching 85.8% in November 2024. Oral administration expands treatment choice through small molecule inhibitors designed for sustained daily dosing across selected patients.

Nissen and colleagues reported enrollment of 178 patients across a Phase 2 zerlasiran study in November 2024. Moderate enrollment supported biomarker assessment without establishing fewer major cardiovascular events across routine care. Limited outcome evidence may delay prescribing confidence among clinicians and reimbursement authorities.

American Heart Association reported in March 2026 stating lipoprotein(a) concentrations of 250 nmol/L are associated with at least a two-fold increased long-term risk of heart attack or stroke. Clear risk thresholds strengthen specialist testing pathways and support treatment evaluation among patients carrying substantial inherited cardiovascular risk.

How are country CAGRs aligned in lipoprotein(a) lowering therapies market?

Country or Market	CAGR
United States	10.6%
United Kingdom	10.1%
Japan	9.4%
South Korea	7.8%
Germany	6.6%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in the lipoprotein(a) lowering therapies market?

Country comparison shows a gradual step-down across the profiled forecasts. United States records the highest CAGR followed by United Kingdom and Japan. South Korea occupies the next position with Germany at the lower end. The four-point spread reflects differences in testing access and clinical trial participation. National positions also indicate varied specialist capacity across cardiovascular care systems.

• United States leads profiled expansion supported by extensive cardiovascular outcome research and specialist participation.
• United Kingdom follows closely aided by organized lipid services and structured secondary prevention programs.
• Japan occupies the middle tier supported by tertiary hospitals and standardized laboratory practices.
• South Korea records a lower forecast pace amid improving specialist guidance and clinical familiarity.
• Germany closes the comparison backed by established apheresis services and gradual therapeutic transition.

Comparable CAGRs may produce different entry conditions across laboratory networks and specialist referral systems. The full report covers North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

Country-wise Analysis

• Sales in the United States are forecast to scale at 10.6% CAGR from 2026 to 2036, driven by deep outcome-trial participation and specialist lipid infrastructure. Academic medical centers provide recruitment capacity for clinical trials across diverse cardiovascular populations. American Heart Association reported fewer than 1% of patients with atherosclerotic cardiovascular disease received lipoprotein(a) testing in July 2025, revealing a large identification gap across secondary prevention services.
• Sector in the United Kingdom is projected to rise at 10.1% CAGR during the study period, influenced by specialist lipid pathways. National cardiology services connect laboratory measurement with organized secondary prevention reviews across high-risk populations. Office for National Statistics recorded 54,097 ischemic heart disease deaths during 2024 in its October 2025 release, sustaining attention toward inherited residual risk.
• Japan’s market is estimated to expand at 9.4% CAGR during the forecast period, aided by tertiary hospital concentration and established laboratory testing pathways. These institutions provide structured settings for inherited-risk assessment and specialist treatment introduction. The Statistics Bureau of Japan reported 36.243 million residents aged 65 years or older during 2024 in its April 2025 release, supporting preventive cardiovascular service demand.
• Industry in South Korean is anticipated to expand at 7.8% CAGR between 2026 and 2036, led by tertiary referral expansion. Lipid society guidance supports risk assessment and treatment readiness across specialized cardiology centers. A Korean Circulation Journal position paper published in January 2026 documented reductions above 80% across 5 Phase 2 agents, strengthening clinician familiarity with targeted medicines.
• The market in Germany is likely to progress at 6.6% CAGR during the assessment period, guided by established apheresis services during gradual pharmacological transition. Specialist lipid clinics provide practical experience with inherited disorders and procedure-intensive treatment pathways. German Federal Statistical Office reported a 23.2% population share for residents aged 60 to under 80 during 2024 in its June 2025 table, sustaining cardiovascular service demand.

Who are notable companies in lipoprotein(a) lowering therapies market?

Novartis develops pelacarsen across cardiovascular outcome and calcific valve disease programs. Eli Lilly advances lepodisiran and muvalaplin through injectable and oral treatment formats. Amgen progresses olpasiran across prevention studies. Ionis Pharmaceuticals contributes antisense discovery experience. Silence Therapeutics adds small interfering RNA development expertise.

Competition in lipoprotein(a) lowering therapies is anticipated to center on outcome evidence and dosing durability. Clinical teams are likely to compare biomarker suppression and safety monitoring prior to treatment adoption. Companies with global trial execution and specialist medical education are expected to receive stronger review attention.

• Novartis and Eli Lilly are expected to gain review attention based on advanced clinical programs covering distinct treatment formats. Specialist teams are likely to assess dosing intervals and cardiovascular outcome design across complete care pathways.
• Amgen is anticipated to compete through olpasiran development across primary and secondary prevention populations. Cardiology programs are projected to compare outcome evidence and treatment durability across high-risk groups.
• Ionis Pharmaceuticals is forecast to support antisense program development depending on established hepatic targeting experience. Partnership execution is expected to influence continuing participation across late-stage cardiovascular development.
• Silence Therapeutics is likely to receive specialist interest due to an advanced small interfering RNA program. Partner selection and trial execution are anticipated to influence future clinical review across cardiovascular services.

Competitive Benchmarking: Lipoprotein(a) Lowering Therapies Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
Novartis AG	High	High	High	Global
Eli Lilly and Company	High	High	High	Global
Amgen Inc.	High	High	High	Global
Ionis Pharmaceuticals, Inc.	Medium	High	Medium	Global
Silence Therapeutics plc	Medium	High	Medium	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Lipoprotein(a) Lowering Therapies Market

• In March 2025, Eli Lilly announced positive ALPACA results for lepodisiran across adults with elevated lipoprotein(a). Company information supported continued development of long-duration dosing across inherited cardiovascular risk pathways.
• In August 2025, Novartis announced Lp(a)FRONTIERS APHERESIS study presentation across European Society of Cardiology Congress. Development assesses pelacarsen as a treatment intended to reduce dependence on lipoprotein apheresis.
• In April 2026, Amgen reported 3 active Phase 3 olpasiran studies across secondary prevention and primary prevention with coronary plaque assessment. Program breadth expands clinical evaluation across distinct elevated lipoprotein(a) populations.

Key Players in Lipoprotein(a) Lowering Therapies Market

Diversified pharmaceutical developers

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.

RNA medicine specialists

• Ionis Pharmaceuticals, Inc.
• Silence Therapeutics plc

Lipoprotein(a) Lowering Therapies Market Report Scope

Coverage field	Report scope
Market breakdown	Lipoprotein(a) Lowering Therapies Market breakdown by therapy type, target, indication, end user, and region
Quantitative Units	USD million in 2026 to USD million by 2036 at CAGR
Market Definition	Lipoprotein(a) lowering therapies include medicines and procedures intended to reduce circulating lipoprotein(a) across cardiovascular risk pathways.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa.
Countries Covered	United States, United Kingdom, Japan, South Korea, Germany, China, and India with 30+ countries included in full analysis.
Key Companies Profiled	Novartis AG, Eli Lilly and Company, Amgen Inc., Ionis Pharmaceuticals, Inc., and Silence Therapeutics plc
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment share and country CAGR with clinical evidence and company participation.

Source: Future Market Insights analysis, 2026.

Lipoprotein(a) Lowering Therapies Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Lipoprotein(a) Lowering Therapies Market by Segments

Lipoprotein(a) Lowering Therapies Market segmented by Therapy Type:

• Antisense Oligonucleotides
• Small Interfering RNA
• PCSK9 Inhibitors
• Lipoprotein Apheresis
• Other Emerging Therapies

Lipoprotein(a) Lowering Therapies Market segmented by Target:

• LPA Gene
• Apolipoprotein(a)
• PCSK9
• LDL Receptor Pathway

Lipoprotein(a) Lowering Therapies Market segmented by Indication:

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Elevated Lipoprotein(a)
• Secondary Cardiovascular Prevention

Lipoprotein(a) Lowering Therapies Market segmented by End User:

• Hospitals
• Specialty Cardiology Clinics
• Ambulatory Care Centers
• Academic & Research Institutes

Lipoprotein(a) Lowering Therapies Market segmented by Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Research Sources and Bibliography

• ClinicalTrials.gov. (2026, June 23). A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen on the progression of calcific aortic valve stenosis.
• Nissen, S. E., Ni, W., Shen, X., Wang, Q., Navar, A. M., Nicholls, S. J., Wolski, K., Michael, L., Haupt, A., & Krege, J. H. (2025, March 30). Lepodisiran - A long-duration small interfering RNA targeting lipoprotein(a). New England Journal of Medicine, 392, 1673-1683.
• Nissen, S. E., Wolski, K., Watts, G. F., Koren, M. J., Fok, H., Nicholls, S. J., Rider, D. A., Cho, L., Romano, S. J., Melgaard, C., & Rambaran, C. (2024, April 8). Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a). JAMA, 331(18), 1534-1543.
• Novartis AG. (2026, June 17). Lipoprotein(a) lowering study of pelacarsen with background inclisiran in participants with established atherosclerotic cardiovascular disease.
• Xu, J., Murphy, S. L., Kochanek, K. D., & Arias, E. (2026, January 29). Mortality in the United States, 2024. NCHS Data Brief, 548, 1-7.
• ClinicalTrials.gov. (2026, May 6). Assessing the impact of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with cardiovascular disease.
• Nicholls, S. J., Ni, W., Rhodes, G. M., Nissen, S. E., Navar, A. M., Michael, L. F., Haupt, A., & Krege, J. H. (2024, November 18). Oral muvalaplin for lowering of lipoprotein(a): A randomized clinical trial. JAMA, 333(3), 222-231.
• Nissen, S. E., Wang, Q., Nicholls, S. J., Navar, A. M., Ray, K. K., Szarek, M., Troquay, R. P. T., Dorresteijn, J. A. N., Fok, H., Rider, D. A., Romano, S. J., Wolski, K., & Rambaran, C. (2024, November 18). Zerlasiran - A small-interfering RNA targeting lipoprotein(a): A Phase 2 randomized clinical trial. JAMA, 332(23), 1992-2002.
• American Heart Association. (2026, March 13). ACC/AHA issue updated guideline for managing lipids, cholesterol.
• American Heart Association. (2025, July 23). Screening for cardiovascular disease marker in community health centers may reduce risk.
• Office for National Statistics. (2025, October 9). Deaths registered in England and Wales: 2024.
• Statistics Bureau of Japan. (2025, April 14). Current population estimates as of October 1, 2024.
• Jang, Y., Lee, J. H., Lee, S. G., Choe, H. J., Park, S. M., Jeong, I. K., & Kim, B. J. (2026, January). A position paper on lipoprotein(a) from the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis. Korean Circulation Journal, 56(1), 9-32.
• German Federal Statistical Office. (2025, June 20). Population by age groups.
• Eli Lilly and Company. (2025, March 30). Lilly lepodisiran reduced levels of genetically inherited heart disease risk factor lipoprotein(a) in adults with elevated levels.
• Novartis AG. (2025, August 18). New Novartis ESC data highlights strength of cardiovascular portfolio.
• Amgen Inc. (2026, April 30). Amgen reports first quarter 2026 financial results.

This bibliography is provided for reader reference and is not exhaustive. Full report contains complete reference records and detailed source review.

This Report Answers

• What therapy types influence demand across specialist cardiovascular pathways?
• How do clinicians evaluate lipoprotein(a) lowering therapies prior to routine use?
• How do country forecasts differ across specialist testing and treatment systems?
• What companies compete through modality depth and clinical evidence?
• How are forecasts validated through independent indicators and primary research?
• What evidence do hospital committees examine prior to treatment adoption?
• How do biomarker durability and outcome evidence influence therapy selection?
• What limits return on investment across specialist cardiovascular programs?
• How do testing pathways influence treatment eligibility across patient populations?
• What company capabilities improve long-term clinical confidence and treatment use?